{"id":"W3137736070","doi":"10.1016/j.jtho.2021.01.1184","title":"P79.05 Phase II Randomized Trial of Neoadjuvant Pembrolizumab +/- Chemotherapy for Operable Stage IA3-IIA Non-Small Cell Lung Cancer","year":2021,"lang":"en","type":"article","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Medicine; Oncology; Lung cancer; Pembrolizumab; Stage (stratigraphy); Internal medicine; Chemotherapy; Immunotherapy; Randomized controlled trial; Neoadjuvant therapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008574639,0.001294674,0.002092704,0.0002781909,0.0003414032,0.001094545,0.0006979503,0.0008504324,0.007169058],"category_scores_gemma":[0.0006563547,0.0005018483,0.001268834,0.0002754902,0.000997599,0.0008895026,0.0003575011,0.002736752,0.00118172],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008728801,"about_ca_system_score_gemma":0.0009870577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001172496,"about_ca_topic_score_gemma":0.00366651,"domain_scores_codex":[0.9997397,0.0001143388,0.00001175624,0.0000542715,0.00001855041,0.00006132758],"domain_scores_gemma":[0.9996922,0.00006082847,0.00006595511,0.00003203605,0.00001603532,0.0001329177],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9561787,0.006439711,0.001004795,0.000439991,0.001000991,0.00003589032,0.00004441892,0.0006936479,0.007779721,0.000262508,0.001539859,0.02457976],"study_design_scores_gemma":[0.9058577,0.0869108,0.003388638,0.0000367918,0.0006422476,0.00004387515,0.00003757876,0.0006579657,0.0007673863,0.0002723326,0.001370163,0.00001461351],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9894023,0.002494494,0.0004926164,0.001043783,0.0006243042,0.001395319,0.0009826182,0.0001183859,0.003446121],"genre_scores_gemma":[0.9875562,0.001549931,0.001238086,0.001255547,0.000312627,0.00177874,0.001419861,0.00003567785,0.004853407],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007169058,"threshold_uncertainty_score":0.02398294,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0230538943609699,"score_gpt":0.4153785200569625,"score_spread":0.3923246256959926,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}